- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
ILSI-Biomed Israel 2007
Needham Biotechnology & Medical Technology Conference 2007
RedChip Small-Cap Investor Conference
BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M. Simes, its president and chief executive officer, will present a corporate overview and update at upcoming conferences. The conferences are:
* The RedChip Small-Cap Investor Conference today, May 30, 2007 at 10:30 a.m. local time at the Ritz Carlton in San Francisco.
* The BioMed 2007 Conference on June 7th at approximately 10:00 a.m. local time at the David Intercontinental Hotel in Tel-Aviv, Israel.
* The Needham Biotechnology and Medical Technology Conference on June 13th at 8:00 a.m. local time at the New York Palace Hotel.
A live audio webcast of BioSante's presentation at the RedChip and Needham conferences can be accessed on the internet by visiting http://www.biosantepharma.com . An archive of these presentations will be available at the same address.
These conferences each feature companies presenting to a diverse group of investors and analysts interested in the biotechnology and pharmaceuticals sectors as well as industry representatives.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel), developed through U.S. Food and Drug Administration (FDA) approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel® (transdermal testosterone gel) in Phase III development for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration.
For more information, please click here
BioSante Pharmaceuticals, Inc.
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanoscale Trojan horses treat inflammation May 24th, 2016
Programmable materials find strength in molecular repetition May 23rd, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016